Article Text

Download PDFPDF
Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis
  1. L F Hsu,
  2. K H Mak,
  3. K W Lau,
  4. L L Sim,
  5. C Chan,
  6. T H Koh,
  7. S C Chuah,
  8. R Kam,
  9. Z P Ding,
  10. W S Teo,
  11. Y L Lim
  1. Department of Cardiology, National Heart Centre, Singapore
  1. Correspondence to:
    Dr K-H Mak, Department of Cardiology, National Heart Centre, Mistri Wing, 17 Third Hospital Avenue, Singapore 168752;


Objective: To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI).

Design: Retrospective observational study with data obtained from prospective registries.

Setting: Tertiary cardiovascular institution with 24 hour acute interventional facilities.

Patients: 202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset.

Interventions: Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%).

Main outcome measures: Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed.

Results: Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis.

Conclusion: Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.

  • angioplasty
  • diabetes
  • fibrinolysis
  • myocardial infarction
  • AMI, acute myocardial infarction
  • CADILLAC, controlled abciximab and device investigation to lower late angioplasty complications
  • EPILOG, evaluation of PTCA to improve long-term outcome by c73E3 glycoprotein IIb/IIIa receptor blockade
  • EPISTENT, evaluation of platelet IIb/IIIa inhibitor for stenting trial
  • GUSTO-IIb, global use of strategies to open occluded coronary arteries in acute coronary syndromes
  • PTCA, percutaneous transluminal coronary angioplasty
  • rt-PA, recombinant tissue-type plasminogen activator
  • TIMI, thrombolysis in myocardial infarction
  • TVR, target vessel revascularisation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society
  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society